d3s-001
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 3, 2022 (NCT05410145)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- GTPase KRasANTAGONIST
KRAS
Chemistry & pharmacology
Loading structure…
SMILES
C=C(F)C(=O)N1CCN(c2nc(OC[C@@]34CCCN3C[C@H](F)C4)nc3c2CO[C@H](c2c(F)c(N)cc(C)c2C(F)(F)F)C3)C[C@@H]1CC#N- Mol. weight
- 679.67 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314913 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07093398 | Phase 1 | Jul 11, 2025 | CMAX Clinical Research, Fortrea, WuXi |
| NCT05886920 | Phase 1 | Jul 10, 2023 | WuXi |
| NCT05410145 | Phase 1 | Aug 3, 2022 | WuXi |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| WuXi | For profit | 3 | 3 | 1 | 2022 |
| CMAX Clinical Research | For profit | 1 | 0 | 1 | 2025 |
| Fortrea | For profit | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1